World Experts and Androgen Study Group Petition JAMA to Retract Misleading Article onTestosterone Therapy. “Gross data mismanagement” led to unreliable results that contradicted 30+ years of medical literature, producing a media frenzy that misled consumers and compromised public health. View Press Release
The retraction request letter was sent to JAMA by the Androgen Study Group and cosigned by three professional medical societies and a highly distinguished international group of 130 scientists and concerned physicians. In the letter addressed to the editor-in-chief of JAMA, Dr. Howard Bauchner, the group cites “gross data mismanagement,” rendering the article “no longer credible.” The article by Rebecca Vigen and colleagues was published in the November 13, 2013 issue of JAMA, entitled “Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels.” The results of this article were widely reported as new evidence that testosterone therapy is associated with cardiovascular risks, resulting in a Food and Drug Administration safety bulletin issued January 31, 2014.
According to Dr. Abraham Morgentaler, Associate Clinical Professor of Urology, Harvard Medical School, and Chairman of the Androgen Study Group, "...this is an extraordinary event,” stated, noting the only continent without a co-signer is Antarctica. “In my 25 years in academic medicine I have never witnessed anything like this response to a journal article. To call for retraction of an article is exceedingly rare. To have several professional societies and so many of the most accomplished experts in the field unite in this action indicates the seriousness of the article’s errors, and the magnitude of damage this article has caused to the public’s perception of testosterone therapy. Lost in the media frenzy that followed this article’s publication is the fact that substantial evidence accumulated over 30 years has shown repeatedly that higher testosterone levels are associated with better cardiovascular outcomes. In the interests of medical science and the public good, JAMA should do the right thing and retract the article..."
To read the full press release of the Androgen Study Group on this serious case of data mismanagement, please follow the link.